As of Aug 31
| -0.20 / -3.18%|
The 5 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 7.75, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +27.47% increase from the last price of 6.08.
The current consensus among 6 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.